FLT3 and acute myeloid leukemia: Specifically, HCT in CR1 is recommended for AML patients with adverse cytogenetics [1, 14] and patients with normal cytogenetics with unmutated NPM1 plus high FLT3-ITD allele ratio or those harbouring RUNX1, ASXL1, or TP53 mutations.